Capricor Therapeutics price target raised to $60 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Capricor Therapeutics (CAPR) to $60 from $24 and keeps a Buy rating on the shares. Capricor rebounded from its July 2025 Complete Response Letter with a decisive clinical win, meeting its primary PUL v2.0 endpoint and the prospectively triggered Left Ventricular Ejection Fraction analysis, positioning its therapy to reach Duchenne muscular dystrophy patients, the analyst tells investors in a research note. With 78% of participants having underlying cardiomyopathy-addressing FDA concerns about sample size-and a conservative approval expectation of mid-2026, shares are likely to trade well into year-end, the firm says.